Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifitegrast for Dry Eye in Ocular GVHD
NCT04792580Phase 1Completed
- Sponsor
- Richard W. Yee, M.D., P.A.
- Start
- Oct 2022
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lifitegrast in dry eye disease (DED), sponsored by Richard W. Yee, M.D., P.A. Primary endpoint: Symptom Assessment in Dry Eye at 4 weeks. Started Oct 2022; status: completed.
02
Drugs
lifitegrast
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04792580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04792580.